NCT02685852View on ClinicalTrials.gov

Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

July 22, 2019

Study Completion Date

July 22, 2019

Conditions
Hyperinsulinemic Hypoglycemia
Interventions
DRUG

Exenatide

Exenatide at a dose of 5 mcg

DRUG

Acarbose

Acarbose at a dose of 25 mg

DRUG

Exenatide Placebo

Placebo for Exenatide

DRUG

Acarbose Placebo

Placebo for Acarbose

Trial Locations (1)

55455

University of Minnesota Medical Center, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT02685852 - Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia | Biotech Hunter | Biotech Hunter